Femara® 2,5 mg NOVARTIS

Description

Contraindications to use

Hypersensitivity to letrozole; endocrine disorders characteristic of the premenopausal period; pregnancy, lactation; children under 18 years of age.

Caution: severe hepatic insufficiency (Child-Pugh class C), severe renal insufficiency (CK<10 ml/min), concomitant use with potent inhibitors of CYP3A4 and CYP2A6 isoenzymes. Concomitant use with drugs with a narrow therapeutic index whose excretion depends mainly on the CYP2C19 isoenzyme.

Use during pregnancy and lactation

Use is contraindicated during pregnancy and lactation.

Use in hepatic impairment

Caution should be exercised in patients with severe hepatic insufficiency (Child-Pugh class C).

Use in renal impairment

Caution should be exercised in patients with severe renal impairment (creatinine clearance < 10 ml/min). The ratio of the expected therapeutic effect to the possible risks of treatment should be carefully considered.